Prevalence and Detection of Neuropsychiatric Adverse Effects During Hepatitis C Treatment

Overview

Journal Int J Clin Pharm

Publisher Springer

Specialties Pharmacology
Pharmacy

Date 2015 Aug 13

PMID 26267215

Citations 3

Authors

Montserrat Masip

Laura Tuneu

Neus Pages

Xavier Torras

Adolfo Gallego

Josep Maria Guardiola

Maria Jose Faus

Maria Antonia Mangues

Affiliations

Soon will be listed here.

Abstract

Background: Current treatment combinations for chronic hepatitis C virus infection still include pegylated interferon and ribavirin despite the new therapeutic options available. Interferon-based treatments are associated with a high incidence of adverse effects. Central nervous system events are among the most frequent adverse drug reactions and their influence on treatment adherence and effectiveness is controversial.

Objective: The aim of the study was to evaluate neuropsychiatric adverse effects of interferon-based treatment for chronic hepatitis C in standard multidisciplinary clinical practice. Risk factors for these adverse effects and their impact on adherence and sustained viral response were also evaluated. Setting Ambulatory care pharmacy in coordination with the liver unit and the infectious diseases unit at a 650-bed tertiary university hospital.

Methods: We included all consecutive patients with chronic hepatitis C who completed treatment with pegylated interferon and ribavirin between 2005 and 2013. All patients underwent a multidisciplinary follow-up during treatment.

Main Outcome Measures: Neuropsychiatric adverse effects were evaluated in relation to severity, management and outcome. The presence of anxiety and depression was evaluated by means of specific tests.

Results: A total of 717 treatments in 679 patients were included. During treatment, we detected 1679 neuropsychiatric adverse effects in 618 patients (86.2 %), generating 1737 clinical interventions. Fifty-seven (3.3 %) neuropsychiatric adverse effects were severe and 2 (0.1 %) were life-threatening (suicidal attempts). Most neuropsychiatric adverse effects (1555 events, 92.6 %) resolved without sequelae. Psychiatric medication was required in 289 patients (40.3 %). Sustained viral response was achieved in 400 cases (55.8 %) and was associated with adherence (OR = 1.942, 95 % CI = 1.235-3.052, p = 0.004). A multivariate analysis did not show any relationship between neuropsychiatric adverse effects and treatment adherence or sustained viral response. A psychiatric history was a strong risk factor for depression, anxiety and other psychiatric disorders during treatment.

Conclusion: Neuropsychiatric adverse effects during interferon-based treatments in patients with chronic hepatitis C were common but mostly mild or moderate. Early detection and accurate multidisciplinary management avoided treatment discontinuation, ensuring adherence and attaining sustained viral response. The identified risk factors could be used to determine patients eligible for interferon-free combinations, thus optimizing health system economics.

Citing Articles

Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis.

Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas M, Mousavi T Exp Ther Med. 2018; 16(2):971-978.

PMID: 30116347 PMC: 6090315. DOI: 10.3892/etm.2018.6255.

Categorization and association analysis of risk factors for adverse drug events.

Zhou L, Rupa A Eur J Clin Pharmacol. 2017; 74(4):389-404.

PMID: 29222712 DOI: 10.1007/s00228-017-2373-5.

Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

Medeiros T, de Morais Salviato C, Rosario N, Saraiva G, Esberard E, Almeida J Int J Clin Pharm. 2017; 39(6):1304-1311.

PMID: 29079938 DOI: 10.1007/s11096-017-0552-1.

References

Udina M, Hidalgo D, Navines R, Forns X, Sola R, Farre M . Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2014; 75(10):e1113-21. DOI: 10.4088/JCP.13r08800. View

Sockalingam S, Abbey S, Alosaimi F, Novak M . A review of sleep disturbance in hepatitis C. J Clin Gastroenterol. 2009; 44(1):38-45. DOI: 10.1097/MCG.0b013e3181b314ea. View

Raison C, Borisov A, Broadwell S, Capuron L, Woolwine B, Jacobson I . Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005; 66(1):41-8. PMC: 1615913. DOI: 10.4088/jcp.v66n0106. View

Fontana R, Kronfol Z, Lindsay K, Bieliauskas L, Padmanabhan L, Back-Madruga C . Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol. 2008; 103(11):2766-75. PMC: 3712502. DOI: 10.1111/j.1572-0241.2008.02106.x. View

Lobo A, Perez-Echeverria M, Artal J . Validity of the scaled version of the General Health Questionnaire (GHQ-28) in a Spanish population. Psychol Med. 1986; 16(1):135-40. DOI: 10.1017/s0033291700002579. View

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y . Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol. 2011; 27(7):1233-40. DOI: 10.1111/j.1440-1746.2011.06965.x. View

. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63(1):199-236. DOI: 10.1016/j.jhep.2015.03.025. View

Evon D, Verma A, Simpson K, Galanko J, Dougherty K, Fried M . Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther. 2008; 27(11):1071-80. DOI: 10.1111/j.1365-2036.2008.03640.x. View

Smith J . Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy. 2008; 28(9):1151-61. DOI: 10.1592/phco.28.9.1151. View

10.

Wu J, Shadbolt B, Teoh N, Blunn A, To C, Rodriguez-Morales I . Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C. J Gastroenterol Hepatol. 2014; 29(6):1258-64. DOI: 10.1111/jgh.12515. View

11.

Hou X, Xu J, Wang J, Yu Y . Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?. PLoS One. 2013; 8(10):e76799. PMC: 3813681. DOI: 10.1371/journal.pone.0076799. View

12.

Haynes R, Taylor D, Sackett D, Gibson E, Bernholz C, Mukherjee J . Can simple clinical measurements detect patient noncompliance?. Hypertension. 1980; 2(6):757-64. DOI: 10.1161/01.hyp.2.6.757. View

13.

Castera L, Constant A, Henry C, Champbenoit P, Bernard P, de Ledinghen V . Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2006; 24(8):1223-30. DOI: 10.1111/j.1365-2036.2006.03107.x. View

14.

Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S . Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012; 57(6):1379-90. DOI: 10.1016/j.jhep.2012.07.037. View

15.

Cabre Serres M, Rudi Sola N, Pontes Garcia C, Vergara Gomez M, Parra Uribe I, Gorgas Torner M . [Multidisciplinary approach as a model for detection and monitoring of psychiatric morbidity in patients treated with interferon and ribavirin]. Farm Hosp. 2014; 38(3):162-8. DOI: 10.7399/fh.2014.38.3.1159. View

16.

Sarkar S, Sarkar R, Berg T, Schaefer M . Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C. Br J Psychiatry. 2014; 206(1):45-51. DOI: 10.1192/bjp.bp.113.141770. View

17.

Carrion J, Gonzalez-Colominas E, Garcia-Retortillo M, Canete N, Cirera I, Coll S . A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol. 2013; 59(5):926-33. DOI: 10.1016/j.jhep.2013.06.019. View

18.

Fried M . Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 Suppl 1):S237-44. DOI: 10.1053/jhep.2002.36810. View

19.

Martin-Santos R, Diez-Quevedo C, Castellvi P, Navines R, Miquel M, Masnou H . De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2007; 27(3):257-65. DOI: 10.1111/j.1365-2036.2007.03568.x. View

20.

Herrero M, Blanch J, Peri J, de Pablo J, Pintor L, Bulbena A . A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003; 25(4):277-83. DOI: 10.1016/s0163-8343(03)00043-4. View